Wall Street Hated 15 Stocks, Earnings Proved Wrong - Jun 3

The Big Picture

Fifteen once-despised stocks surprised Wall Street by reporting earnings that forced analysts to rethink prior calls, and that shift could reshuffle short positions and sector weightings in many portfolios. MarketWatch flags these names as examples where earnings momentum mattered more than prior sentiment, creating windows for revaluation and trading activity.

Investors should note that analyst activity has already followed the news, with price targets and ratings updated on several names. Those moves matter because they change who pays attention and how funds allocate capital.

What's Happening

MarketWatch compiled a list of 15 stocks that had been under pressure from bearish sentiment but reported earnings that contradicted the pessimism. The headline takeaway is not just the beats, but how those beats prompted immediate market and analyst reactions.

• 15, the number of stocks highlighted as having been broadly disliked by Wall Street before their earnings beat expectations, showing the scale of the reversal.
• $90, the price target tied to Abivax SA ($ABVX) after Jefferies moved the stock from Buy to Hold, illustrating how earnings and fundamentals can trigger analyst reassessments.
• $105, the price target tied to Con Edison ($ED) following Mizuho's downgrade from Outperform to Neutral, showing that even defensive utilities are getting fresh scrutiny.
• $3, a key numeric data point included in the briefing materials, useful for valuation comparisons or per-share metrics in small-cap examples on the list.

Beyond the raw counts and price targets, the story emphasizes that earnings surprises matter more when a company has been written off. Analysts like Jefferies and Mizuho have already shifted ratings and price targets on names such as $ABVX and $ED. Stifel's coverage of Fulcrum Therapeutics ($FULC) is also listed in the analyst context, reflecting active coverage across sectors.

Why It Matters For Your Portfolio

When a beaten-down stock outperforms, it can trigger rapid repricing, short-covering rallies, and renewed institutional interest. For your portfolio, that means there may be opportunity in select names, but also higher volatility as consensus gets rebuilt.

Who should care: growth investors looking for turnaround stories, value investors seeking cheap fundamentals that are improving, and traders who can exploit short-covering moves. Analysts are already taking notice, which increases liquidity and the likelihood of price-target changes that move shares.

Risks To Consider

• Reversal May Be Short-Lived: Earnings beats that follow deeply negative sentiment can produce sharp rallies that fade if subsequent guidance disappoints.
• Analyst Actions Can Be Mixed: As shown by Jefferies, Mizuho, and Stifel moves, ratings and price targets can move in different directions, creating conflicting signals for investors.
• Valuation Traps: Stocks that registered a $3 or similarly low per-share metric may look inexpensive but could reflect structural problems not solved by one quarter.

What To Watch Next

Investors should track upcoming catalysts and fresh analyst commentary that could sustain or reverse the post-earnings moves. The market will reward clarity on demand, margins, and forward guidance.

• Analyst Reports: Continued updates from firms like Jefferies, Mizuho, and Stifel on $ABVX, $ED, and $FULC will signal whether the earnings beats have lasting impact.
• Follow-Up Guidance: Look for next-quarter guidance and management commentary from the names on the list, since a single beat without positive guidance may not hold.
• Sector Reflows: Watch whether sector ETFs and fund managers reallocate capital toward these previously hated stocks, which can amplify moves.

The Bottom Line

• Several previously unloved stocks surprised on earnings, forcing analysts to update ratings and price targets; that dynamic can create trading and research opportunities.
• Analyst activity already shows mixed responses, with Jefferies shifting $ABVX guidance to $90 and Mizuho adjusting $ED to $105; track these changes for sentiment clues.
• Investors should treat these names as volatile re-ratings rather than clear long-term turnarounds until follow-up guidance and fundamentals confirm a trend.
• Short-term traders may find setups in momentum and short-covering, while longer-term investors should demand repeated evidence of improving fundamentals before reallocating capital.
• Data points like $3 per-share figures and other valuation metrics are useful starting points for deeper due diligence rather than reasons to move immediately.

FAQ

Q: Which stocks made the MarketWatch list?

A: MarketWatch highlighted 15 previously disliked stocks that beat earnings; specific names mentioned in the analyst context include $ABVX, $ED, and $FULC, among others.

Q: How should I use analyst rating changes like the $90 and $105 price points?

A: Use revised price targets and rating changes as signals that professional coverage is shifting, then compare those targets to your valuation work and risk tolerance before adjusting positions.

Q: What short-term catalysts could move these stocks next?

A: Key catalysts include follow-up quarterly guidance, additional analyst notes from firms such as Jefferies and Mizuho, and sector-level fund rebalancing that can amplify moves.